 Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia ALL, with full data from the AUTO1-AL1 study expected in 2022 Company intends to partner AUTO3, ahead of progressing into the next phase of development Company adjusting its workforce and infrastructure footprint to align with AUTO1 prioritization 